Interferon and anti-TNF therapies differentially modulate amygdala reactivity which predicts associated bidirectional changes in depressive symptoms

Kevin A. Davies1,2 · Ella Cooper1 · Valerie Voon3 · Jeremy Tibble4 · Mara Cercignani1 · Neil A. Harrison1,5

Received: 21 October 2019 / Revised: 24 April 2020 / Accepted: 15 May 2020 / Published online: 26 May 2020 © The Author(s) 2020. This article is published with open access

Abstract
A third of patients receiving Interferon-α (IFN-α) treatment for Hepatitis-C develop major depressive disorder (MDD). Conversely, anti-Tumor Necrosis Factor (TNF) therapies improve depression providing key empirical support for the “inflammatory theory” of depression. Heightened amygdala reactivity (particularly to negatively valanced stimuli) is a consistent finding within MDD; can predict treatment efficacy and reverses following successful treatment. However, whether IFN-α and anti-TNF enhance/attenuate depressive symptoms through modulation of amygdala emotional reactivity is unknown. Utilizing a prospective study design, we recruited 30 patients (mean 48.0 ± 10.5 years, 21 male) initiating IFN-α treatment for Hepatitis-C and 30 (mean 50.4 ± 15.7 years, 10 male) anti-TNF therapy for inflammatory arthritis. All completed an emotional face-processing task during fMRI and blood sampling before and after their first IFN-α (4-h) or anti-TNF (24-h) injection and follow-up psychiatric assessments for 3 months of treatment. IFN-α significantly increased depression symptoms (Hamilton Depression Rating Scale HAM-D) at 4 weeks (p < 0.001) but not 4-h after first dose (p > 0.1). Conversely, anti-TNF significantly improved depressive symptoms (Hospital Anxiety and Depression Rating Scale HADS) at both 24-h (P = 0.015) and 12 weeks (p = 0.018). In support of our a-priori hypothesis, both IFN-α and anti-TNF significantly modulated amygdala reactivity with IFN-α acutely enhancing right amygdala responses to sad (compared with neutral) faces (p = 0.032) and anti-TNF conversely decreasing right amygdala reactivity (across emotional valence) (p = 0.033). Furthermore, these changes predicted IFN-induced increases in HAM-D 4 weeks later (R² = 0.17, p = 0.022) and anti-TNF-associated decreases in HADS at 24-h (R² = 0.23, p = 0.01) suggesting that actions of systemic inflammation on amygdala emotional reactivity play a mechanistic role in inflammation-associated depressive symptoms.

Introduction
Inflammation is increasingly implicated in the etiology of depression [1]. Patients with major depressive disorder (MDD) show activated inflammatory pathways including raised pro-inflammatory cytokines [2], acute phase proteins [3], chemokines, and adhesion molecules [4] in blood as well as increased pro-inflammatory cytokines in cerebrospinal fluid (CSF) [5, 6]. Conversely, patients with pro-inflammatory diseases such as rheumatoid arthritis experience a high burden of depressive symptoms, that improves following suppression of peripheral inflammation with cytokine blockers such as the anti-Tumor Necrosis Factor (anti-TNF) therapies [7]. Experimentally induced inflammation can also acutely impair mood and induceanhedonia, effects that have been linked to changes in amygdala, subgenual cingulate, and striatal reactivity to emotional or hedonically valanced stimuli [8–10]. A similar pattern of
Interferon and anti-TNF therapies differentially modulate amygdala reactivity which predicts associated...

neuroimaging changes is also observed in MDD [11, 12], suggesting that actions of inflammation on the neural processing of emotionally valanced stimuli may, if prolonged, predispose to the later development of depression.

Studies of patients treated with prolonged courses of pro-inflammatory cytokines e.g., interferon-alpha (IFN-α) provide arguably the most compelling data for an etiological role for inflammation in depression. When used to treat hepatitis-C or malignant melanoma, a third of patients develop major depression, typically within 4–8 weeks of treatment onset [13, 14]. They also provide important mechanistic insights into how actions of systemic inflammation on the brain may precipitate depression. For example, acute (3-h) cortisol and adrenocorticotropic hormone (ACTH) responses to IFN-α predict the subsequent development of depression implicating the brain’s stress circuitry [15]. Chronic IFN-α also induces the enzyme indoleamine-2,3-dioxygenase to reduce serotonin synthesis and increase metabolically active tryptophan metabolites such as kynurenine [16, 17] and induces circumscribed increases in striatal glucose uptake [18], glutamate concentration [19], and dopamine turnover [20]. However, though cross-sectional, and even a recent prospective study, have repeatedly associated these striatal changes with impairments in motivation and subjective fatigue [21], none has identified a clear association with emergence of depressive symptoms suggesting an alternate neurobiological substrate for these effects.

In contrast, numerous studies have now demonstrated anti-depressant properties of anti-cytokine therapies when used in the context of chronic inflammatory disorders (e.g., inflammatory arthritis) [7, 22] or MDD with raised peripheral inflammatory markers [23]. Preclinical investigations of their mechanistic actions are more limited, though support clinical observations of a rapid (within 24 h) action of anti-TNF therapies on the brain, including importantly, inhibition of amygdala reactivity to emotionally salient (pain) stimuli [24]. This later finding is notable as it highlights a key component of the brain stress-circuitry and complements human studies in MDD where heightened amygdala reactivity to emotionally salient stimuli is a characteristic feature [11, 25]. Furthermore, in MDD, heightened amygdala reactivity has been shown to be highly dynamic, resolving rapidly on successful depression treatment [25] and providing value in predicting therapeutic success [26]. This has led to the proposal that amygdala emotional reactivity may provide the neurobiological substrate for the mood congruent processing bias integral to this disorder [26].

Interestingly, this dynamic nature of amygdala reactivity may underscore why the neural substrates for IFN-α-induced depression have remained obscure. To date, studies of IFN-α-induced depression have focused on techniques such as Fluorodeoxyglucose (FDG)-PET that are highly sensitive to resting metabolic activity but not neural reactivity. Consequently, actions on reactivity of neural circuits implicated in emotional processing would go un-detected and only become evident using task-based techniques such as fMRI. In support of this, mild inflammatory challenges increase the emotional reactivity [8] but not resting metabolic activity (FDG-PET) [27] of brain regions sub-serving emotional processing including amygdala and subgenual cingulate [8]. Furthermore, though MDD patients typically display heightened reactivity to emotionally valanced stimuli within brain regions sub-serving emotional processing (particularly amygdala) [11, 25] they rarely demonstrate a corresponding change in resting metabolic activity [28].

To address whether acute changes in amygdala emotional reactivity induced by IFN-α/anti-TNF therapies predispose to the later development/resolution of depressive symptoms we recruited 30 patients scheduled to start IFN-α based therapy for chronic hepatitis-C infection and 30 patients scheduled to start anti-TNF based therapy for inflammatory arthritis. All completed an emotional-face processing task known to reliably engage affective brain systems during fMRI on two separate sessions: 1 week before treatment initiation and 4/24 h after their first dose of IFN-α/anti-TNF therapy respectively. All were then followed up for 3 months. We hypothesized that IFN-α would acutely increase, and anti-TNF acutely decrease amygdala reactivity to emotionally valanced faces. Furthermore, we predicted that if acute changes in emotional reactivity predispose to emergence/resolution of depressive symptoms induced by IFN-α/anti-TNF treatments respectively, these changes should also predict subsequent changes in depressive symptoms.

Materials and methods

Participants

Thirty individuals (21 male, mean 48.0 ± 10.5 years) were recruited before initiating IFN-α-based therapy for Hepatitis-C and 30 (10 male, mean 50.4 ± 15.7 years) before initiating anti-TNF therapy for inflammatory arthritis (25 Rheumatoid arthritis, 2 Psoriatic Arthritis, 3 Ankylosing spondylitis). All were fluent in English, aged 18–69 years and fulfilled National Institute for Health and Care Excellence (NICE) guidelines for starting IFN-α-based therapy or anti-TNF therapy. Participants had a baseline psychiatric evaluation of current mental state and previous psychiatric history, using the Mini Neuropsychiatric Inventory. Hepatitis-C participants were excluded if they were receiving treatment for depression at study enrollment, had a history of psychotic or autoimmune illness, substance
mislabeled in the last 6 months, were co-infected with human immunodeficiency virus, or had any cause for liver disease other than hepatitis C. Inflammatory arthritis patients were excluded if they had co-morbid systemic lupus erythematosus, untreated thyroid disease, stroke or multiple sclerosis, or were receiving treatment for depression at study enrollment. The study was approved by Cambridge Central (12/EE0491) and South East Coast (11/LO/1320) National Research Ethics Committees. All subjects provided written informed consent.

Study design

The study utilized a prospective cohort design. Participants underwent an emotional face processing task during fMRI, blood draw and behavioral testing at baseline (median 8 days before treatment) and after their first IFN-α (4 h) or anti-TNF (24 h) injection timed to coincide with reported onset of subjective symptoms (but not depressive symptoms per-se) and preclinical data confirming actions of IFN-α and anti-TNF on the brain at these timepoints [15, 21, 24, 29]. Inflammatory response and depressive symptoms were evaluated at each fMRI visit and after 12 weeks of therapy in all participants. IFN-α treated patients underwent additional behavioral assessments at 4 and 8 weeks to capture the more rapid symptom evolution in this group. Consistent with previous studies, profile of mood states (POMS), Hamilton Depression Rating Scale (HAM-D), state and trait anxiety inventory (STAI) and fatigue visual analog scale (fVAS) were used to index changes in mood, depression/ anxiety and fatigue respectively in the IFN-α treated group.

Arthritis patients underwent a broader assessment designed to capture additional changes in disease activity and pain. This included: POMS, Hospital Anxiety and Depression Scale (HADS), pain and fatigue VAS (pVAS, fVAS), Beck Depression Inventory (BDI), and DAS28. Bath Ankylosing Spondylitis Functional Index and Bath Ankylosing Spondylitis Disease Activity Index or Psoriasis Area and Severity Index and Psoriatic Arthritis Response Criteria as appropriate. They were also given the option to return for a third scanning session at 12 weeks to assess whether any acute changes in emotional reactivity were sustained after 3 months of treatment (24 completed this additional session).

Emotional face processing task

During each scanning session participants viewed 37 unique positive (happy), 37 negative (sad), and 37 neu-trally valanced face stimuli, presented in random order. Each stimulus was displayed for 3 s with a jittered 7-s inter-trial interval. During stimulus display participants were instructed to introspect on how the displayed emotional facial expression reflected their current emotional state. They indicated their response using a button press (not at all/somewhat/quite a lot) immediately after image offset. Two sets of face stimuli were used, counterbalanced across the two imaging sessions. All participants were briefed on the task prior to scanning and all completed the task well.

fMRI

T2*-weighted echo planar images (EPIs) were acquired on a 1.5 T Siemens Avanto scanner, equipped with a 32-channel phased-array receive-only head coil using a −30° tilted acquisition to reduce orbitofrontal dropout. Each volume provided whole brain coverage (34 interleaved ascending 3 mm slices, 0.6 mm inter-slice gap, echo-time 34 ms: TR 2.52 s). High-resolution T1-weighted anatomical scan was acquired using a magnetization-prepared-rapid-acquisition-gradient-echo sequence to aid group level anatomical localization. EPIs were analyzed in an event related manner using SPM12. Preprocessing consisted of spatial realignment, segmentation, and normalization of the mean EPI image to a standard template then 8 mm3 spatial smoothing. The ARTifact Detection Toolbox (http://cibr.stanford.edu/tools/human-brain-project/artrepair-software.html) [30] was used to identify motion outliers, which were then interpolated in the general linear model. Subject-specific realignment parameters were modeled as covariates of no interest.

We defined left and right amygdala as our primary a priori ROIs based on the prior literature in idiopathic MDD [25, 26], inflammation-associated mood change [8] and depression [31] and preclinical use of anti-TNF [24]. Left and right subgenual cingulate were included as additional ROIs given their reported role in idiopathic depression [32, 33] and inflammation-associated mood change [8]. Masks were produced using the WFU Pickatlas (http://fmri.wfubmc.edu/software/pickatlas).

Stimulus onsets were modeled as 3s events and convolved with a canonical hemodynamic response function. Linear contrasts of regression coefficients were computed at the individual subject level then taken to group level flexible factorial ANOVA or t-tests as appropriate. Main effects of viewing emotional faces (happy, sad, neutral compared with implicit baseline) were first tested in each group using paired-sample t-tests. Effects of IFN-α and anti-TNF on the processing of all emotional faces (happy, sad, and neutral) and on sad compared with neutral expressions were then tested in flexible factorial ANOVAs (factors: drug (IFN, anti-TNF), time (pre, post drug).

Finally, we performed a regression analysis to investigate whether acute actions of pro (IFN-α) or anti-inflammatory challenges (anti-TNF) on the neural processing of
emotionally valanced stimuli predicted the later development/attenuation of depressive symptoms. To minimize variance induced by change in medication (e.g., starting an antidepressant), we restricted this analysis to the next assessment i.e., change in depressive symptoms at 4 weeks in IFN-α group and 12 weeks in the arthritis group. Specifically, we investigated whether acute changes in neural reactivity to sad compared with neutral stimuli or to all emotional expressions within amygdala or subgenual cingulate ROIs predicted the subsequent development of depression symptoms.

**Multiple comparisons**

Whole-brain corrected cluster significance was determined using robust Family Wise Error (FWE) correction. Only clusters surviving whole brain or ROI small-volume FWE correction $\alpha < 0.05$ after thresholding at an uncorrected statistical threshold of $p < 0.001$ are reported.

**Behavioral analyses**

The primary outcome variable was change in depressive symptoms (HAM-D at 4 weeks in the in the IFN-α group and HADSD at 12 weeks in the anti-TNF group). Data are also reported for changes in each of the other measures. Effects of IFN-α/anti-TNF on depressive symptoms and cytokines were analyzed in SPSS 22.0 using repeated measures ANOVAs and subsequent paired sample $t$-tests. Mauchly’s test of sphericity was performed, and results reported followed Greenhouse-Geisser correction where appropriate. Change in arthritis disease activity is reported for the rheumatoid arthritis patients using the DAS28-CRP $= 0.56 \times \sqrt{\text{TEN28}} + 0.28 \times \sqrt{\text{SW28}} + 0.36 \times \ln(\text{CRP} + 1) + 0.014 \times \text{GH} + 0.96$. Where TEN = Tender joint count, SW = Swollen joint count and GH = Patient Global Health assessment from 0 (best) to 100 (worst).

**Cytokine analyses**

Blood (20 mL) was drawn into Vacutainer tubes containing ethylenediaminetetraacetic acid (EDTA) anticoagulant, centrifuged at 1300 rpm for 10 min and plasma was removed, aliquoted, and frozen at $-80^\circ$C before analysis. Plasma IFN-α was measured using high sensitivity VeriKine™ ELISA (human IFN-α multi-subtype kit, PBL Assay Science, Piscataway, USA). Interleukin-6 (IL-6), Tumor Necrosis factor (TNF), IL-1β and IL-10 using high sensitivity Quantikine® ELISAs (R&D Systems, Abingdon, UK) and IL-1 Receptor antagonist (IL-1Ra) using Quantikine® ELISA. Cytokines were selected based on the prevailing literature to provide an index of both pro- and anti-inflammatory responses.

**Results**

**Cytokine response**

As anticipated, IFN-α was associated with a significant increase in plasma IFN-α (from mean (± s.e.) 3.12 ± 0.95 pmol/L at baseline to 43.26 ± 7.66 pmol/L at 4 h, $t_{(29)} = 5.12, p < 0.001$). Plasma TNF was not significantly altered at this time point (2.51 ± 0.37 to 2.95 ± 0.48 pmol/L, $t_{(29)} = -0.85, p = 0.40$). However, we did observe an approximately threefold increase in IL-6 (1.85 ± 0.35 to 4.98 ± 0.69 pmol/L, $t_{(29)} = 4.41, p < 0.001$) as well as significant increases in IL-1 receptor antagonist (IL-1ra) from 191.57 ± 28.52 to 592.20 ± 113.12 pmol/L ($t_{(29)} = 3.66, p = 0.001$) and IL-10 from 0.85 ± 0.18 to 1.40 ± 0.25 pmol/L ($t_{(29)} = 2.85, p = 0.008$) demonstrating a broader pro and anti-inflammatory cytokine response to IFN-α (Fig. 1).

Cytokine responses to anti-TNF (Fig. 2) broadly mirrored those to IFN-α with a halving of IL-6 at 24 h (6.41 ± 1.72 to 3.05 ± 0.97 pmol/L, $t_{(27)} = -2.55, p = 0.017$) as well as significant reductions in IL-1ra and IL-10 (766.33 ± 249.22 to 490.74 ± 195.21 pmol/L, $t_{(27)} = -2.06, p = 0.049$ and 0.30 ± 0.13 to 0.22 ± 0.12 pmol/L, $t_{(27)} = -2.53, p = 0.017$) respectively. TNF concentrations showed a non-significant increase at this time point likely reflecting increased circulating bound TNF (0.94 ± 0.45 to 3.19 ± 1.42 pmol/L, $t_{(27)} = 1.47, p = 0.15$).

**Depression symptoms**

IFN-α significantly increased depressive symptoms (HAM-D: $F_{(2,116)} = 29.72, p < 0.001$) rising from 7.00 ± 1.32 at baseline to peak 16.90 ± 1.75 at 8 weeks, with significant effects observed from 4 weeks until the end of treatment. However, we observed no significant increase in depression symptoms (HAM-D) immediately after IFN-α (7.00 ± 1.32 to 7.50 ± 1.42, $t_{(29)} = 0.89, p = 0.38$), nor any association between acute changes in depression (4 h) and subsequent development of depression symptoms at 4, 8, or 12 weeks.

Conversely, anti-TNF significantly reduced depressive symptoms (HADSD) ($F_{(2,50)} = 4.81, p = 0.012$) from 6.31 ± 3.07 at baseline to trough 4.82 ± 3.34 at 12 weeks with significant effects observed at both 24 h ($t_{(28)} = 2.60, p = 0.015$) and 12 weeks ($t_{(28)} = 2.51, p = 0.018$). Similar effects were also observed in cognitive symptoms of depression measured with the BDI (24 h ($t_{(28)} = 3.25, p = 0.003$), 12 weeks ($t_{(28)} = 3.78, p = 0.001$). HADS anxiety subscale showed a trend toward a reduction in anxiety (24 h: $t_{(28)} = 1.94, p = 0.063$; 12 weeks: $t_{(28)} = 3.25, p = 0.053$) (Fig. 2). Interestingly, improvement in depressive symptoms at 24 h was not associated with a significant change in joint pain (pVAS $t_{(28)} = 0.96, p = 0.347$).
However, there was a significant improvement in the composite measure of disease activity (DAS28-CRP) that includes a subjective rating of global health at this time-point ($t(28) = 2.92$, $p = 0.007$). Clinical and demographic data are summarized in Table 1.

**Processing of emotionally valanced stimuli**

Emotional face stimuli (happy, sad, neutral) in both IFN-α and anti-TNF groups robustly activated the matrix of neural structures encompassing occipital visual cortices, bilateral fusiform face area and bilateral amygdala identified in previous meta-analysis [34] (Fig. 3a, d); and evoked strong activations in bilateral dorsal anterior cingulate and superior parietal lobule and left primary motor cortex confirming task engagement (SI Tables 1 and 2).

We observed no significant main effect of IFN-α (viewing all emotional face stimuli at 4 h > baseline) (Table 2). However in line with our hypothesis, the interaction between IFN-α and processing of negative (sad) compared with neutrally valanced stimuli demonstrated a significant effect within the right amygdala ($[18,-6,-28]$, Z = 4.19, FWE small volume correction $p = 0.032$), with sad (compared with neutral) faces inducing a significantly greater right amygdala response 4 h after IFN-α compared with baseline (Fig. 3b, Table 2). Significant interactions were also observed at the whole brain level in bilateral visual cortices and right fusiform face areas confirming a broader impact of IFN-α on negatively valanced emotional processing. Conversely, anti-TNF was associated with a significant decrease in right (and left) amygdala reactivity that was observed across all emotional expressions (main effect of IFN) but not significantly different for sad compared with neutral expressions (i.e., no interaction) (Fig. 3e, Table 2). See SI Tables 3–6 for additional results and results at 3 months.

To explore how these acute IFN-α/anti-TNF-induced changes in amygdala reactivity contribute to the emergence/resolution of depressive symptoms, we next investigated whether they predicted changes in depressive symptoms at 4/12 weeks, respectively. This regression analysis demonstrated that IFN-α induced changes in amygdala reactivity (sad compared with neutral stimuli) significantly predicted the subsequent development of depressive symptoms at 4 weeks (HAM-D, $F_{(1,29)} = 5.84$, adjusted $R^2 = 0.17$, $p = 0.022$). Specifically, patients

---

**Fig. 1 Mood and cytokine responses to interferon-alpha.** Violin plot illustrating data distributions (probability density), median and interquartile ranges. **a** Hamilton Depression Rating Scale (HAMD) and State Anxiety (STAI) at baseline, 4 h, 4, 8, and 12 weeks after starting IFN-α based therapy. *P* values relate to comparison with baseline values. **b** Log plasma Interleukin (IL)-6, Tumor Necrosis factor (TNF), IL1 receptor antagonist (IL1ra) and IL-10 concentration at baseline and 4 h after the first injection of IFN-α.
showing the greatest increase in neural reactivity to sad facial expressions after the first dose of IFN-α subsequently showed the greatest increase in HAM-D depressive symptoms (Fig. 3c). Conversely anti-TNF induced changes in amygdala reactivity at 24 h (across emotional expressions) significantly correlated with co-incident changes in depressive symptoms (HADSd, $F_{(1,28)}=7.81$, adjusted $R^2=0.23$, $p=0.01$) but not changes in depressive symptoms 12 weeks later ($p>0.1$) (Fig. 3f). Of note, this significant anti-TNF induced reduction in amygdala reactivity was sustained at 12 weeks (SI Table 3). At this later timepoint, the correlation with coincident change in depressive symptoms persisted, but more weakly and only at trend level in this smaller group (HADSd, $F_{(1,23)}=2.94$, adjusted $R^2=0.12$, $p=0.10$). Results reported were not significantly influenced by sex differences (see SI Results, SI Table 7 and SI Fig. 1).

**Discussion**

Here we show that pro- and anti-inflammatory therapies differentially reorient amygdala emotional reactivity. This bidirectional reorientation in amygdala reactivity occurred rapidly (within 4 h of IFN-α injection and 24 h of anti-TNF) and scaled with changes in depressive symptoms. Following IFN-α, this was observed as a selective increase in right amygdala responsivity to negative (sad) versus neutrally valanced expressions and occurred prior to any change in depressive symptoms. Furthermore, it predicted the subsequent development of depressive symptoms, explaining ~17% of the increase in HAM-D symptoms 4 weeks later. In contrast, anti-TNF therapy acutely decreased amygdala reactivity across the range of emotional expressions (happy, sad and neutral) with no evidence of any selective effect on sad versus neutral expressions. Again, this change in

---

**Fig. 2 Mood and cytokine responses to anti-TNF therapy.** Violin plot illustrating data distributions (probability density), median and interquartile ranges. a Hospital Anxiety and Depression Rating Scale (HADS) total and depression (HADSd) and anxiety (HADSa) subscales at baseline, 24 h and 12 weeks after starting anti-TNF therapy. b Log plasma Interleukin (IL)-6, Tumor Necrosis factor (TNF) and IL1 receptor antagonist (IL1ra) at baseline, 24 h and 12 weeks after starting anti-TNF therapy. c Becks Depression Inventory (BDI), visual analog scale for pain (pVAS) and composite disease activity score (DAS28 CRP) at baseline, 24 h and 12 weeks after starting anti-TNF therapy.
amygdala reactivity scaled with changes in depressive symptoms (improvement). However, in this group changes in depressive symptoms occurred early (within 24 h) and co-occurred with changes in amygdala reactivity, confirming the association between coincident changes in amygdala reactivity and depressive symptoms but did not provide additional predictive power for further change in depressive symptoms 12 weeks later. Together, these findings extend evidence from experimentally-induced inflammation that link changes in amygdala, subgenual cingulate and striatal emotional reactivity to acute changes in mood [8, 9]. By demonstrating that selective changes in amygdala function precede the development of depressive symptoms our findings have relevance beyond IFN-α treatment to suggest a cytokine-mediated mechanism through which sustained systemic inflammation may also predispose to the development of depression.

Within depression, heightened amygdala reactivity to negatively valanced emotional stimuli (sad faces and words) is a reliable finding [25, 28] and has been proposed to mediate the characteristic mood-congruent processing bias [35]. It has value in predicting therapeutic response to CBT [26], normalizes following successful treatment with selective serotonin reuptake inhibitors [35] and in patients in remission serves as a physiological vulnerability marker for relapse [35]. However, the amygdala is also critical to the initiation and integration of broader stress responses [36]. This includes a central role in integrating behavioral and hypothalamic–pituitary–adrenal endocrine responses to extrinsic (e.g., psychological) stressors [36] but also modulation of cortisol stress responses to intrinsic stressors including systemic cytokine challenge [37]. This later finding is noteworthy given earlier evidence that acute ACTH and cortisol responses to Interferon can also predict the later emergence of depressive symptoms [15] and provides a potential mechanistic link between these and our current data.

How IFN-α and anti-TNF act on the brain to alter amygdala reactivity and why they show differential specificity (Increased sensitivity to sad versus neutral expressions, versus decreased sensitivity to all emotional stimuli,

**Table 1** Demographics of the Hepatitis-C and Inflammatory Arthritis Groups.

|                       | Arthritis (Baseline) | Arthritis (12-Wks) | p value | Hep-C (Baseline) | Hep-C (4-Wks) | p value |
|-----------------------|----------------------|--------------------|---------|-----------------|--------------|---------|
| Age (years)           | 50.4 ± 15.7          | 48.0 ± 10.5        | 0.39    |                 |              |         |
| Sex                   |                      |                    |         |                 |              |         |
| Male                  | 10                   | 4                 | 0.005   |                 |              |         |
| Female                | 20                   | 9                 |         |                 |              |         |
| Depression Scorea     | 6.3 ± 3.1            | 4.8 ± 3.3          | 0.018   | 7.0 ± 7.1       | 15.6 ± 8.0   | <0.001  |
| F-VAS                 | 66.3 ± 20.5          | 42.0 ± 24.8        | <0.001  | 34.8 ± 26.9     | 63.4 ± 29.0  | <0.001  |

Additional assessments in the Inflammatory Arthritis group

|                       |                      |                    |         |                 |              |         |
| P-VAS                 | 57.7 ± 23.5          | 39.8 ± 27.5        | 0.001   | –               | –            | –       |
| BDI                   | 14.4 ± 8.1           | 9.4 ± 8.2          | 0.001   | –               | –            | –       |
| DAS28-CRP             | 5.7 ± 1.1            | 4.3 ± 1.5          | <0.001  | –               | –            | –       |

Additional details for the Inflammatory Arthritis group

| Diagnosis             |                       |                   |
|-----------------------|-----------------------|-------------------|
| Rheumatoid Arthritis (RA) | 25                    |                   |
| Psoriatic Arthritis (PsA) | 2                     |                   |
| Ankylosing Spondylitis (AS) | 3                     |                   |

| Treatment             |                       |                   |
|-----------------------|-----------------------|-------------------|
| Adalimumab            | 13 (11 RA, 2 PsA)     |                   |
| Certolizumab          | 10 (10 RA)            |                   |
| Etanercept            | 5 (3 RA, 2 AS)        |                   |
| Golimumab             | 2 (1 RA, 1 AS)        |                   |

Data represent mean ± standard deviation. F-VAS and P-VAS fatigue- and pain- Visual Analog Scale scores (0–100) respectively; BDI: Beck’s Depression Inventory; DAS28-CRP (28 Item Disease Activity Score).

aValues denote HADSd Hospital Anxiety and Depression Rating Scale (Depression component) for Inflammatory Arthritis and HAM-D Hamilton Depression Rating Scale for Hepatitis-C patients.
respectively) remains incompletely understood, though may be usefully informed by the rodent and non-human primate literature. Firstly, both IFN-α and TNF have been shown to cross the rodent blood-brain barrier (BBB) [38]. Three-fold increases in CSF IFN-α have also been reported from 3 h of systemic IFN-α injection in rhesus monkeys [39] and similar elevations in CSF IFN-α observed after 12 weeks of IFN-α therapy in humans [17]. Further, in rodents, intraperitoneal injection of even modest amounts of IFN-α rapidly induces IFN-sensitive genes within the brain [40, 41] and increases neuronal firing rates within amygdala and other brain regions [29]. Within the hypothalamus, IFN-α can differentially modulate neuronal firing rates in lateral (hunger) and ventro-medial (satiety) related nuclei [29]. Whether, the selective effects of IFN-α on negatively valanced information relates to similar differential effects within the amygdala remains to be determined.

In contrast, raised pro-inflammatory cytokines (particularly TNF and IL-1β) have been reported in CSF in humans and rodent models of Inflammatory Arthritis [42] with recent CSF proteomic analysis showing that anti-TNF therapy reduces CSF concentrations of a range of acute phase and immune response proteins [43]. Interestingly, TNF has also been shown to mediate homeostatic synaptic scaling, the mechanism used by the brain to allow individual neurons to modulate their overall action potential firing rate in response to chronically elevated/reduced activity within their neural circuit [44]. More specifically, TNF increases neuronal post-synaptic AMPA receptor expression resulting in a uniform increase to the strength of all synapses to the cell. Theoretically, this mechanism may underlie why we observed a global reduction in amygdala reactivity (across emotional expressions) following anti-TNF therapy.

Use of two complimentary patient groups initiating pro- (IFN-α) and anti- (anti-TNF) inflammatory therapies is a major strength of our study that enabled us to demonstrate that systemic inflammation can rapidly and bidirectionally reorient amygdala reactivity to emotionally valanced

---

**Fig. 3 Effects of interferon-alpha and anti-TNF on brain emotional reactivity.** Top row Hepatitis-C patients initiating interferon-alpha (IFN). Bottom row inflammatory arthritis patients initiating anti-TNF (aTNF) a + d Main effect of viewing emotional (sad, happy, neutral) faces versus implicit baseline pre and post IFN and aTNF, respectively. Amygdala responses are indicated with red circles. b Increase in right amygdala reactivity to sad versus neutral stimuli 4 h after IFN compared with baseline (pre IFN). Inset shows mean contrast estimate for sad > neutral contrast for the right amygdala ROI at baseline and 4 h after IFN. c Correlation between acute change in right Amygdala reactivity to Sad versus neutral face stimuli (4 h minus baseline) and subsequent change in HAM-D score (4 weeks minus baseline). d Decrease in right amygdala reactivity to ALL emotional stimuli 24 h after IFN compared with baseline (pre-IFN). Inset shows mean contrast estimate for happy (H), sad (S) and neutral (N) facial expressions for the right amygdala ROI at baseline and 24 h after anti-TNF. e Correlation between change in right Amygdala reactivity to ALL emotional stimuli (24 h after aTNF minus baseline) and coincident change in HADS depression (HADSd) score (24 h minus baseline). Color scale bars denote Z score.
Acute changes in amygdala reactivity predicted only concurrent (but not future) change in depressive symptoms in this group. Nevertheless, our current study extends prior studies implicating acute stress responses in IFN-α-induced depression [15] and provides a potential brain mechanism through which bidirectional changes in peripheral inflammation contribute to the development/resolution of depressive symptoms.

Acknowledgements This Article was funded by a Wellcome Trust Fellowship awarded to NAH (Grant Number: 093881/Z/10/Z). We thank Majella Keller, Alexandra File, and Catherine Wood for their contribution to the recruitment of patients.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immun. 2016;16:22–34.
2. Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun. 2015;49:206–15.
3. Sluzewska A, Rybakowski JK, Sobieska M, Wiktorowicz K. Concentration and microheterogeneity glycoporphins of alpha-1-acid glycoprotein in major depressive disorder. J Affect Disord. 1996;39:149–55.
4. Leighton SP, Nerurkar L, Krishnadas R, Johnman C, Graham GJ, Cavanagh J. Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis. Mol Psychiatry. 2018;23:48–58.
5. Levine J, Barak Y, Chpengappa KN, Rapoport A, Rebey M, Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology. 1999;34:171–6.
6. Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry. 2009;66:287–92.
7. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in
psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367:29–35.
8. Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry. 2009;66:407–14.
9. Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irwin MR. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry. 2010;68:748–54.
10. Harrison NA, Voon V, Cercignani M, Cooper EA, Pessiglione M, Critchley HD. A neurocomputational account of how inflammation enhances sensitivity to punishments versus rewards. Biol Psychiatry. 2016;80:73–81.
11. Siegle GJ, Steinhauser SR, Thase ME, Stenger VA, Carter CS. Can’t shake that feeling: fMRI assessment of sustained amygdala activity in response to emotional information in depressed individuals. Biol Psychiatry. 2002;51:693–707.
12. Harrison NA. Brain structures implicated in inflammation-associated depression. Curr Top Behav Neurosci. 2017;31:221–48.
13. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961–6.
14. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, et al. Neurobehavioral effects of interferon-α in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 2002;26:643–52.
15. Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH. Association of exaggerated HPA axis response with depression during interferon-α alpha therapy. Am J Psychol. 2003;160:1342–5.
16. Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D, et al. Interferon-α-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol Psychiatry. 2003;54:906–14.
17. Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G, et al. CSF concentrations of brain tryptophan and kynurenes during immune stimulation with IFN-α: relationship to CNS immune responses and depression. Mol Psychiatry. 2010;15:393–403.
18. Capuron L, Pagnoni G, Demetrashvili MF, Lawson DH, Fornwald FB, Woolwine B, et al. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-α therapy. Neuropsychopharmacology. 2007;32:2384–92.
19. Haroon E, Woolwine BJ, Chen X, Pace TW, Parekh S, Spivey JR, et al. IFN-α-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy. Neuropsychopharmacology. 2014;39:1777–85.
20. Capuron L, Pagnoni G, Drake DF, Woolwine BJ, Spivey JR, Crowe RJ, et al. Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon αlfa administration. Arch Gen Psychiatry. 2012;69:1044–53.
21. Dowell NG, Cooper EA, Tibble J, Voon V, Critchley HD, Cercignani M, et al. Acute changes in striatal microstructure predict the development of interferon-α induced fatigue. Biol Psychiatry. 2015;79:320–8.
22. Kappelmann N, Lewis G, Dantzer R, Jones PB, Khandaker GM. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry. 2018;23:335–43.
23. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31–41.
24. Hess A, Axmann R, Rech J, Finzel S, Heindl C, Kreitz S, et al. Blockade of TNF-α rapidly inhibits pain responses in the central nervous system. PNAS. 2011;108:3731–6.
25. Sheline YI, Barch DM, Donnelly JM, Ollinger JM, Snyder AZ, Mintun MA. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry. 2001;50:651–8.
26. Siegle GJ, Carter CS, Thase ME. Use of fMRI to predict recovery from unipolar depression with cognitive behavior therapy. Am J Psychiatry. 2006;163:735–8.
27. Harrison NA, Doeller CF, Voon V, Burgess N, Critchley HD. Peripheral inflammation acutely impairs human spatial memory via actions on medial temporal lobe glucose metabolism. Biol Psychiatry. 2014;76:585–93.
28. Price JL, Drevets WC. Neurocircuitry of mood disorders. Neuropsychopharmacology. 2010;35:192–216.
29. Dafny N, Prieto-Gomez B, Dong W-Q, Reyes-Vazquez C. Interferon modulates neuronal activity recorded from the hypothalamus, thalamus, hippocampus, amygdala and the somatosensory cortex. Brain Res. 1996;734:269–74.
30. Mazaika PK, Hoef F, Glover GH, Reiss AL. Methods and software for fMRI analysis of clinical subjects. In: Proceedings of Human Brain Mapping Conference 2009.
31. Mehta ND, Haroon E, Xu X, Woolwine BJ, Li Z, Felger JC. Inflammation negatively correlates with amygdala-ventromedial prefrontal functional connectivity in association with anxiety in patients with depression: Preliminary results. Brain Behav Immun. 2019;73:725–30.
32. Drevets WC, Price JL, Simpson JR, Todd RD, Reich T, Vannier M, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997;386:824–7.
33. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Maharun RK, Jerabeket PA, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry. 1999;156:675–82.
34. Fusar-Poli P, Placentino A, Carletti F, Landi P, Allen P, Surguladze S, et al. Functional atlas of emotional faces processing: a voxel-based meta-analysis of 105 functional magnetic resonance imaging studies. J Psychiatry Neurosci. 2009;34:418–32.
35. Victor TA, Furey ML, Fromm SJ, Ohman A, Drevets WC. Relationship between amygdala responses to masked faces and mood state and treatment in major depressive disorder. JAMA Psychiatry. 2013;70:31.
36. Herman JP, Figueiredo H, Mueller NK, Ulrich-Lai Y, Ostrander MM, Choi DC, et al. Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo–pituitary–adrenocortical responsiveness. Front Neuroendocrinol. 2003;24:151–80.
37. Xu Y, Day TA, Buller KM. The central amygdala modulates hypothalamic–pituitary–adrenal axis responses to systemic interleukin-1beta administration. Neuroscience. 1999;94:175–83.
38. Pan W, Banks WA, Kastin AJ. Permeability of the blood–brain and blood–spinal cord barriers to interferons. J Neuroimmunol. 1997;76:105–11.
39. Felger JC, Alaghe O, Hu F, Mook D, Freeman AA, Sanchez MM, et al. Effects of interferon-alpha on rhesus monkeys: a non-human primate model of cytokine-induced depression. Biol Psychiatry. 2007;62:1324–33.
40. Wang J, Campbell IL. Innate STATI-dependent genomic response of neurons to the antiviral cytokine alpha interferon. J Virol. 2005;79:8295–302.

SPRINGER NATURE
41. Wang J, Campbell IL, Zhang H. Systemic interferon-α regulates interferon-stimulated genes in the central nervous system. Mol Psychiatry. 2008;13:293–301.

42. Lampa J, Westman M, Kadetoff D, Agreus AN, Le Maiètre E, Gillis-Haegerstrand C, et al. Peripheral inflammatory disease associated with centrally activated IL-1 system in humans and mice. PNAS. 2012;109:12728–33.

43. Estelius J, Lengqvist J, Ossipova E, Idborg H, Le Maiètre E, Andersson MLA, et al. Mass spectrometry-based analysis of cerebrospinal fluid from arthritis patients - immune-related candidate proteins affected by TNF blocking treatment. Arthritis Res Ther. 2019;21:60–71.

44. Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF-α. Nature. 2006;440:1054–9.